Rilonacept, also known as IL-1 Trap (marketed by Regeneron Pharmaceuticals under the trade name Arcalyst), is an interleukin 1 inhibitor. Rilonacept was given "orphan drug" status by the United States Food and Drug Administration and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle–Wells syndrome and neonatal onset multisystem inflammatory disease (It is not approved in the U.S. on this indication).

On May 8th, 2012 an FDA Advisory Panel voted 11-0 against the approval of rilonacept for the treatment of gout, stating that the benefits did not outweigh the risks associated with the drug ...Wikipedia

 

 

 

Manufacturer's Website: Not Available                                                                                                     Average retail cost: $21,000/month

 

 

Search Terms: Arcalyst, rilonacept, interleukin 1 inhibitor, cryopyrin-associated periodic syndromes (CAPS), familial cold autoinflammatory syndrome, Muckle–Wells syndrome, neonatal onset multisystem inflammatory disease